integrin for vedolizumab and interleukin-12/23 pathways for ustekinumab) than the primary biological class, anti-tumour necrosis factor alpha (anti-TNF) agents. As the armamentarium for IBD increases in coming years, it will become important to understand factors associated with response in order to best position and personalise therapy.
| INTRODUCTION
Biological agents have become the mainstay of therapy for moderate to severely active IBD. For many years, the only class of biologicals used in IBD treatment was anti-tumour necrosis factor alpha (anti-TNF) agents. However, 2 new biological drugs that target different inflammatory pathways have been recently approved for IBD: vedolizumab and ustekinumab.
Vedolizumab is a humanised monoclonal gut-selective antibody against a4b7 integrin and inhibits the trafficking of inflammatory cells to the intestine. Vedolizumab was efficacious at inducing and maintaining remission in three phase 3, randomised controlled trials (GEMINI) in Crohn's disease (CD) and ulcerative colitis (UC). [1] [2] [3] Vedolizumab was approved for the treatment of adult patients with moderate-to-severe UC or CD who have an inadequate response to, lose response to or are intolerant to conventional therapy (corticosteroids and immunomodulators) or anti-TNF therapy. In real-world cohorts from several groups from North America and Europe, primary response to vedolizumab was typically evaluated at week 14 after induction with rates of clinical remission and clinical response ranging between 24%-36% and 49%-64% in CD, and 23%-39% and 43%-57% in UC, respectively. [4] [5] [6] [7] In longer term follow-up from the GEMINI trials, about 20% of both CD and UC patients who initially responded had discontinued vedolizumab because of lack of efficacy. 8, 9 In real-world cohorts, vedolizumab therapy was stopped or optimised during the maintenance phase due to lack or loss of response in 36%-54% of IBD patients. [10] [11] [12] [13] Ustekinumab is a monoclonal IgG1 antibody against the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23) that targets both the T-helper 1 and T-helper 17 pathways involved in the pathogenesis of CD. A large phase 2b (CERTIFI) and three pivotal phase 3 studies (UNITI) have shown that ustekinumab is effective as an induction and maintenance therapy for CD. 14, 15 In 2016, ustekinumab was approved for the treatment of moderately to severely active CD in adults who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with an anti-TNF, or who failed or were intolerant to treatment with one or more anti-TNF. In real-world observational studies, patients were treated off-label and received highly variable induction and maintenance dosing, thus limiting the generalisability of results.
The rates of response were reported to be as high as 84% and remission rates as high as 35% at end of induction, with loss of response in around one-third of patients during maintenance. [16] [17] [18] [19] [20] [21] These 2 drugs appear to have a favourable safety profile and are well tolerated. 15, 22 They provide alternative options other than anti-TNF therapy in the treatment of moderate to severe IBD. However, similar to anti-TNF agents, a significant number of patients do not respond to these drugs and their place relative to anti-TNF therapy (before or after) remains unclear. The purpose of this review is to summarise the current literature regarding the predictors of primary and secondary response to vedolizumab and ustekinumab in CD and UC adult patients, and to compare with the current predictors to anti-TNF, in order to identify patients who are most likely to benefit from these specific therapies. patients with a Harvey-Bradshaw index (HBI) score > 10 or a Mayo score > 9 at baseline were less likely to achieve steroid-free clinical remission at weeks 14 6 and 54. 13 In addition, a German cohort including 97 active CD patients, identified a low HBI score and no hospitalisation in the past 12 months as independent predictors of clinical remission at week 14. 5 In the Israeli real-world experience with 130 CD patients, mild clinical activity was associated with an increased likelihood of achieving clinical remission at week 14.
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Among others factors studied, subgroup analyses of GEMINI 2
showed higher clinical remission rates in men, younger patients (age < 35 years) and those with a shorter duration of disease ( < 7 years) in CD. 1 In the VICTORY consortium cohort, which included 212 CD patients at 7 sites across the United States, patients with baseline severe disease activity, smoking history and active perianal disease were less likely to achieve clinical remission during maintenance therapy. 23 The literature on predictors to anti-TNF is consistent with these results. Disease severity in UC and complicated phenotype in CD have been reported as negative predictors of response to anti-TNF agents. 24, 25 In contrast, short disease duration in CD before initiation of anti-TNF 26, 27 and younger age have been associated with better responses. • Response and remission at week 14 response or remission. 4 Amiot et al showed that UC patients with an elevated CRP and leukocytosis were less likely to achieve steroidfree clinical remission at week 14 and during maintenance therapy respectively. 6, 13 A national study based on the Swedish National Quality Registry for IBD (SWIBREG), a large prospectively maintained national quality registry from 45 hospitals, was conducted to describe the patient population that was treated with vedolizumab to assess the long-term drug continuation rate and to identify predictors of drug discontinuation. 11 In total, 246 patients were included (147 CD and 92 UC). Elevated CRP at initiation was associated with a higher risk for vedolizumab discontinuation due to lack or loss of response. Finally, a lower CRP or faecal calprotectin at week 14, as compared to baseline predicted clinical remission at week 54 in a large German cohort. 
| Initial response to vedolizumab
Patients who achieved early response to vedolizumab appear to be more likely to have a long-term response. In the GETAID cohorts, patients who had a clinical response at week 6 were more likely to achieve steroid-free clinical remission at week 14 and 54 in both CD and UC. 6, 13 In addition, response and remission status at week 14 predicted clinical remission at week 54 in German cohort. 12 Early clinical response and mucosal healing with anti-TNF have also been found as positive predictors for long-term response. [32] [33] [34] Mucosal healing should be evaluated as a predictor of response in future studies with vedolizumab.
| Concomitant therapies
In French cohorts (GETAID), patients with concomitant steroid use at time of vedolizumab induction were less likely to achieve steroidfree clinical remission at week 14 in CD patients 6 and at week 54 for CD and UC. 13 Stallmach et al found that steroid use for less than 25% of the time within the last 6 months predicted a higher likelihood of clinical remission at week 54 in UC. 12 During the maintenance phase, the Boston cohort showed that the addition of an immunomodulator after induction in CD was a significant predictor of clinical response or remission to vedolizumab at week 54. 10 However, this was not found in other studies. In a population pharmacokinetic and pharmacodynamic analysis, use of concomitant immunosuppression did not affect vedolizumab clearance or concentration, which differs from effects seen with anti-TNF. 35 Indeed, concomitant treatment with immunomodulator with anti-TNF was associated with improved trough levels, reduced production of antibodies infliximab and improved clinical outcomes. 30, 36 In addition, in the real-world VICTORY cohort where 54% of patients were treated with concomitant immunomodulator and/or steroids, no differences were noted in terms • of clinical response or remission compared to vedolizumab alone. 23 The question of whether to add or continue an immunomodulator in combination with vedolizumab therapy remains uncertain.
| Previous anti-TNF exposure
Subgroups analyses of GEMINI 1 and 2 showed higher remission rates in patients with no prior anti-TNF failure in UC and CD. 1,2 Two post hoc analyses from the GEMINI studies reported the efficacy of vedolizumab in UC and CD patients based on prior anti-TNF history. 37, 38 Vedolizumab demonstrated a consistent benefit for inducing and maintaining clinical response and remission in both TNF-na€ ıve and TNF-failure patients over placebo. However, rate of response and remission were numerically higher in CD patients receiving vedolizumab as a first biological agent than in patients who had experienced TNF failure (48.4% and 26.6% vs 39.7% and 21.8% at week 10).
These higher rates persist at week 52. 38 The same results were found in UC patients, where patients naive to anti-TNF had higher rates of response (absolute difference [AD]: 15.5%) than patients with anti-TNF failure (AD: 7.0%) compared to placebo at week 6, but the AD in remission rates observed was the same in the maintenance therapy.
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In the real-world VICTORY cohort, previous anti-TNF exposure was associated with lower rates of clinical remission and mucosal healing in CD patients. 23 Similarly, in UC patients, the VICTORY consortium observed that prior anti-TNF exposure was associated with a decreased chance of clinical response and remission during maintenance therapy. 39 Stallmach et al showed that patients who were na€ ıve to anti-TNF were more likely to achieve clinical remission at week 54 only in UC patients. 12 Recently, a clinical prediction model and tool for 
| Pharmacological aspects
There is a well-established correlation between serum trough levels of anti-TNF and clinical response. 42, 43 In the same way, post hoc analyses of GEMINI study data revealed a positive relationship between vedolizumab exposure and efficacy. Higher vedolizumab concentrations were associated with higher clinical remission rates at week 6. 44 The exposure-efficacy relationship was steeper for UC than CD, when comparing results from GEMINI 1 and 2. This relationship was affected by several factors, including previous anti-TNF use, baseline albumin concentration and CRP. The remission probability was approximately 10% higher in TNF-na€ ıve patients. In addition, in a prospective study from 2 French hospitals that included 47 patients with CD or UC receiving induction therapy with vedolizumab, low trough levels of vedolizumab at week 6 ( < 19.0 mg/ mL) were associated with need for additional doses (given at week 10 and then every 4 weeks). 45 score ≥ 7 at induction were less likely to achieve clinical response, as were patients with stricturing disease. 16 The same group performed a retrospective cohort study of 104 CD patients who responded to ustekinumab induction and continued long-term maintenance. 20 
| Initial response to ustekinumab
In a Spanish cohort, the initial response to ustekinumab was associated with clinical benefit at the end of follow-up at a median of 10 months (interquartile range: 5-21). 19 This finding is consistent with data from the CERTIFI study. Similar to vedolizumab, immunogenicity rates with ustekinumab use appear to be low: 2.3% at 1 year in the UNITI studies 15 and 0% at 26 weeks in the Canadian experience. 
| Concomitant immunomodulator
In a retrospective observational study performed in tertiary French (GETAID) and Swiss centres, 122 CD patients refractory to anti-TNF therapy were studied. Concomitant use of immunosuppressant at baseline was a predictive factor of clinical benefit at 3 months. 18 
| Previous anti-TNF or immunomodulator exposure
In phase 3 clinical trials, the rates of clinical response and remission at induction were higher in patients who had failed or were intolerant to conventional therapy (majority na€ ıve to anti-TNF; UNITI-2) than in patients who had failed anti-TNF therapy (UNITI-1). 15 There is no data in observational studies comparing the response to ustekinumab between anti-TNF naive and exposed patients, since all patients included in these studies had failed or were intolerant to anti-TNF therapy.
Regarding prior immunomodulator exposure, a Spanish cohort found that having previously used 2 or more immunosuppressive drugs was associated with a long-term clinical benefit during maintenance (median follow-up: 10 months). 
